Evidence map›Paper›PMID 30165831›Full record

SynthesisBMC infectious diseases2018

Laboratory methods for case finding in human psittacosis outbreaks: a systematic review.

Annelies A Nieuwenhuizen, Frederika Dijkstra, Daan W Notermans, Wim van der Hoek

Open access · goldAbstract readSystematic Review
In one paragraph

Synthesis in BMC infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed, 3 pooled it
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 3 syntheses or guidelines pooled it, 99 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Rapid diagnosis ofExperimental and therapeutic medicine · 2026
    Article
  5. Chlamydia psittaci Meningitis, Chile, 2023.Emerging infectious diseases · 2026
    Article
  6. Targeted next-generation sequencing improves diagnosis and antimicrobial stewardship in Chlamydia psittaci pneumonia.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026
    Article
  7. Observational
  8. Article
  9. Article
  10. Frontiers in cellular and infection microbiology · 2026
    Review
  11. Successful azithromycin treatment ofFrontiers in pharmacology · 2026
    Article
  12. Clinical Features of 186 Cases ofInfection and drug resistance · 2026
    Article
  13. Review
  14. Community-AcquiredCase reports in infectious diseases · 2025
    Article
  15. Zoonotic potential ofFrontiers in veterinary science · 2025
    Article
  16. Article
  17. Article
  18. Diagnosis ofFrontiers in medicine · 2025
    Article
  19. Atypical pneumonia (Review).Experimental and therapeutic medicine · 2024
    Review
  20. Article

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Annelies A NieuwenhuizenCentre for Infectious Diseases, Epidemiology and Surveillance, Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.ORCID http://orcid.org/0000-0001-7883-0977
Frederika DijkstraCentre for Infectious Diseases, Epidemiology and Surveillance, Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands. frederika.dijkstra@rivm.nl.
Daan W NotermansCentre for Infectious Diseases Research, Diagnostics and Laboratory Surveillance, Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.
Wim van der HoekCentre for Infectious Diseases, Epidemiology and Surveillance, Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.
National Institute for Public Health and the Environment · NL

Funding

Centre for Infectious Disease Control (NL) V/150207ZonMw 522001002
6 · The paper itself

Abstract

backgroundPsittacosis outbreak investigations require rapid identification of cases in order to trace possible sources and perform public health risk assessments. In recent outbreaks in the Netherlands, such investigations were hampered by the non-specificity of laboratory testing methods to identify human Chlamydia psittaci infections.

methodA systematic search of PubMed and Scopus databases of literature published between 01 January, 1986 and 03 July, 2017 was done to find best practices of laboratory-testing methods used in psittacosis outbreaks of two or more human cases. Reference lists of included articles were hand searched to identify additional articles.

resultsThirty-seven eligible articles were identified, describing 44 human psittacosis outbreaks in 12 countries. Laboratory tests performed were PCR (with various targets), serologic tests (complement binding reactions, ELISA's, immunofluorescence tests and immuno-peroxidase tests) and culture, in various combinations. The literature provided no 'gold standard' laboratory testing strategy to identify recent human C. psittaci infections. In most psittacosis outbreaks, for a considerable number of cases (or tested individuals in an exposed cohort), C. psittaci infection could not be confirmed, nor excluded as causative pathogen. None of the testing strategies was found to be suitable for (nearly) full case finding.

conclusionPCR enables rapid identification of human psittacosis patients and helps source finding by genotyping but has the disadvantage that sensitivity is high only in the acute phase. In outbreak situations, there is often a time delay and therefore, there is a need for new serologic testing methods next to PCR, with good specificity and sensitivity. Moreover, serum is easier to collect than the preferred diagnostic materials for PCR. A serologic test that can reliably confirm infection status without the necessity of convalescent serum sampling would enhance case finding, source tracing, identification of risk factors and assessment of burden of disease in various settings.

Indexed as

AnimalsBirdsChlamydophila psittaciClinical Laboratory TechniquesDatabases, FactualDisease OutbreaksDNA, BacterialHumansPolymerase Chain ReactionPsittacosisDNA, BacterialChlamydia psittaciDiagnosticsDisease outbreaksEpidemiologyPsittacosisSystematic reviewZoonoses.

Identifiers

PMID30165831
PMCPMC6118005
OpenAlexW2889092997

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.